Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 10/20 | 0.42 |
| ▸ | CDK2 | P24941 | 10/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.42 |
| ▸ | AURKA | O14965 | 8/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.35 |
| ▸ | EP300 | Q09472 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16123821 | 0.86 | CCNA2 (0.53) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL17234814 | 0.84 | CCNA2 (0.47) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL16123822 | 0.81 | AURKA (0.47) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL17232797 | 0.81 | AURKA (0.39) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL16127155 | 0.81 | RBP4 (0.41) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL17518296 | 0.81 | CCNA2 (0.39) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL17232720 | 0.80 | RBP4 (0.41) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL17232769 | 0.80 | CCNA2 (0.53) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL17232682 | 0.79 | CGAS (0.39) | CCNA2CDK2CCNA1AURKACREBBP | |
| SCHEMBL17232718 | 0.79 | RBP4 (0.42) | CCNA2CDK2CCNA1AURKACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1978804-B1 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8653059-B2 | Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2001883-B1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20110224195-A1 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| US-7750034-B2 | Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7678905-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090270467-A1 | Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
| EP-2001883-A2 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007126745-A2 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070232676-A1 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232676-A1 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | CCNA2 3407/4885CDK2 1617/4885CCNA1 4110/4885 |
| US-20090270467-A1 | Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | CCNA2 1760/4885CDK2 736/4885CCNA1 2588/4885 |
| US-20110224195-A1 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | CCNA2 3018/4885CDK2 1288/4885CCNA1 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.